PASG Q2 2024 Earnings — Passage Bio, Inc. Revenue & Financial Results | Market Cap Arena

PASGPassage Bio, Inc.

$29M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$17M

Net Income

-$16M

EPS (Diluted)

$-5.18

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$125M

Total Liabilities

$35M

Stockholders' Equity

$91M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$17M	-$25M	+31.6%
Net Income	-$16M	-$24M	+33.0%